

DOST

Event occurred on: [REDACTED]

Created on: [REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

Training Pattern: 100%

Clinical oncology training grade: MTI

Specialty: Clinical oncology

Location: [REDACTED]

Training grade

MTI

Case description

65 years old gentleman with cT2N1Mo rectal cancer treated with long course chemoradiotherapy. He progressed in retroperitoneal lymph nodes after chemoradiotherapy. He was planned neoadjuvant chemotherapy with Oxaliplatin and Capecitabine.

Systemic therapy regimen

Neoadjuvant chemotherapy with Capecitabine and Oxaliplatin

Oxaliplatin 130mg/m² IV Day 1 + Capecitabine 1000mg/m² BD to start on day 1 in the evening and continue for 14 days. To be repeated every three weekly.

Dose reduction of Capecitabine by 20% (800mg/m² BD)

Continuation or initiation?

Initiation

Trainee comments

You should include any comments on the assessment you have carried out and your own performance before you submit this request to your chosen assessor.

Once your assessor has completed and submitted the assessment it will be placed into your timeline as complete.

New version available!
Please reload the page before
downloading the PDF to avoid any errors. ✕

Trainee's comments - comment on your performance and any action required

I have assessed his fitness for chemotherapy and gathered the details of previous treatment. He had dehydration and renal impairment with capecitabine given concurrently with radiotherapy. I have also checked his chronic medication and advised him to stop Sulfasalazine and di methyl fumarate, which he has been taking for psoriasis in view of potential interaction with Capecitabine and increased risk of immunosuppression and side effects.

In view of previous renal impairment, I have reduced the dose of Capecitabine by 20%. I have also reviewed his blood investigation which were satisfactory to to go ahead with chemotherapy.

Attach files

Role: Assessor

Specialty: Clinical oncology

Assessor's Name

Assessors Role

Consultant

Assessor's comments

Please state areas of good practice and areas for development

What was done well:

Excellent summary of case with thorough assessment of previous co-morbidities and toxicities.

What are the suggested areas for development?

Continue excellent thorough management.

Agreed action plan

Continue excellent thorough management.

New version available!
Please reload the page before
downloading the PDF to avoid any errors.

Systemic anti-cancer therapy (SACT) prescribing competence rating

Level 4 - Can initiate and prescribe systemic anticancer therapy for patients with a range of malignancies, while operating within local guidelines or within the context of a clinical trial. Can demonstrate appropriate involvement of the patient and carers in decision-making regarding treatment

SACT prescribing competence ratings align with the [Academy of Medical Royal Colleges recommendations document April 2015](https://www.aomrc.org.uk/wp-content/uploads/2016/05/Achieving_Safer_Prescription_Cytotoxic_Agents_0415.pdf) (https://www.aomrc.org.uk/wp-content/uploads/2016/05/Achieving_Safer_Prescription_Cytotoxic_Agents_0415.pdf).

Overall entrustment level

Level 4 - Entrusted to act unsupervised

Assessor's declaration

By submitting this form you are agreeing that you observed this procedure

Attach files

New version available!

Please reload the page before
downloading the PDF to avoid any errors.